Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06035679 |
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : February 28, 2024
|
Sponsor:
Youzhi Zhu
Information provided by (Responsible Party):
Youzhi Zhu, First Affiliated Hospital of Fujian Medical University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | November 30, 2026 |
Estimated Study Completion Date : | November 30, 2026 |